COMPOUND MARKS Sample Clauses

COMPOUND MARKS. To the extent that Licensee is using a Compound Mark xx of the date of this License Agreement, it may continue to use the Licensed Marks and Licensed Trade Dress in the Compound Mark xxxing the Initial Periods hereunder applicable to the Product with respect to which such Compound Mark xx used. During the Transition Period hereunder (if applicable), Licensee shall, if it desires to continue to use a Compound Mark, xxe the Transition Brand in lieu of the Licensed Marks and Licensed Trade Dress to create a Transition Compound Mark. Xx the end of the Transition Period hereunder, Licensee shall cease all use of the Licensed Marks and Licensed Trade Dress in the Transition Compound Mark, xxbject to the inventory depletion rules relating to the Transition Period.
Sample 1
AutoNDA by SimpleDocs
COMPOUND MARKS. (i) To the extent that Licensee or Licensee's customer is using a Compound Mark xx of the Effective Date, it may continue to use the Licensed Marks in the Compound Mark xxxing the period of time described in clause 2.1(a) ("Initial Period") hereunder applicable to the Agere Products with respect to which such Compound Mark xx used. During the period of time described in clause 2.1(b) ("Transition Period"), Licensee shall, if it desires to continue to use a Compound Mark, xxe a Transition Logo in lieu of the Licensed Marks to create a Transition Compound Mark. Xx the end of the Transition Period, Licensee shall, if it desires to continue to use a compound mark, xxe the Agere Marks in lieu of the Transition Logo to create a new compound mark, xxnership of which shall belong exclusively to Agere and Lucent will have no rights therein. At the end of the Initial Period or Transition Period (as the case may be), Licensee shall cease all use of the Licensed Marks or Transition Logo (as the case may be) in the Compound Marks, subject to the inventory depletion allowances set forth herein.
Sample 1
COMPOUND MARKS. (i) To the extent that Licensee is using a Compound Mark xx of the date of this Agreement, it may continue to use the Licensed Marks in the Compound Mark xxxing the Initial Period hereunder applicable to the Avaya Products with respect to which such Compound Mark xx used. After the Initial Period, Licensee shall, if it desires to continue to use the Compound Mark, xxe the Corporate Identification Mark xx lieu of the Licensed Marks to create a new Compound Mark, xxnership of which shall belong exclusively to Avaya and Lucent will have no rights therein. At the end of the Initial Period hereunder, Licensee shall cease all use of the Licensed Marks in the Compound Mark, xxbject to the inventory depletion rules set forth herein.
Sample 1

Related to COMPOUND MARKS

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Product Trademarks BMS shall be solely responsible for the selection (including the creation, searching and clearing), registration, maintenance, policing and enforcement of all trademarks developed for use in connection with the marketing, sale or distribution of Products in the Field in the Territory (the “Product Marks”). BMS shall own all Product Marks, and all trademark registrations for said marks.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Joint Technology The Parties agree that, in order to effectuate the provisions of Section 4.4.2, subject to any exclusive licenses granted hereunder, (a) the non-use provisions of this Article 9 shall not apply to each Party’s use of Joint Technology, and (b) each Party may disclose the Joint Technology to Third Parties who are under terms of confidentiality no less strict than those contained in this Agreement.

  • Licensed Patent Rights The term “Licensed Patent Rights” shall mean rights arising out of or resulting from:

  • Patent Rights The term “

  • Licensed Rights (a) (i) BNYM hereby grants to Company a limited, nonexclusive, nontransferable license to access and use the Licensed System in the United States through its employees (other than as expressly permitted otherwise by Section 2.1(a)(ii) below), solely in accordance with applicable Documentation, through the interfaces and telecommunication lines designated by BNYM, strictly for the internal business purposes of the Company, solely in support of the Core Services and solely for so long as any applicable fees are paid by Company.

  • Background IP Each Party will own all right, title and interest in its Background IP.

  • Joint Patent Rights If not already established under the Research Collaboration Agreement, prior to either Party filing any Patent Right disclosing Joint Program Technology or Joint TAP Platform Improvements, the Parties shall establish a patent committee (the “Patent Committee”) comprised of at least one (1) representative of each Party for the purpose of facilitating the preparation, filing, prosecution, maintenance and defense of Joint Patent Rights. As agreed upon by the Parties, meetings of the Patent Committee may be face-to-face or may be conducted by teleconferences or videoconferences, from time to time as needed. The Patent Committee will be the forum through which the Parties coordinate their respective obligations to each other described in Sections 5.2.2 and 5.2.3 hereof and in this Section. In the event the Parties conceive or generate any Joint Program [***] Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Confidential Treatment Requested by CytomX Therapeutics, Inc. Technology or Joint TAP Platform Improvements, the Parties shall promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon, which Party will control filing, prosecution and maintenance of such patents and how to pay for the filing, prosecution and maintenance of such patents. It is presumed that CytomX will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint Program Technology or Joint Unconjugated Probody Platform Improvements, and that ImmunoGen will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint TAP Platform Improvements or Joint Conjugation Probody Platform Improvements. Neither Party will file any Joint Patent Right without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. The Party controlling filing and prosecution of any such Joint Patent Right (a) shall keep the other Party informed regarding each Patent Right, (b) shall consider in good faith any recommendations made by the other Party in regard to the filing, prosecution or maintenance of any such Patent Right and (c) shall not unreasonably refuse to incorporate any recommendations made by the other Party in regard to such filing, prosecution or maintenance.

Time is Money Join Law Insider Premium to draft better contracts faster.